# Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%

> **NCT07689149** · PHASE4 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Kidney Transplantation Recipients
- HLA Sensitization

## Interventions

- **DRUG:** BiTE (CD19 x CD3 Bispecific Antibody)
- **DRUG:** BiTE (BCMA x CD3 Bispecific Antibody)

## Key facts

- **NCT ID:** NCT07689149
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689149, "Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*